Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares ...

The latest biotech stock to explode in price, Nektar Therapeutics (NASDAQ: NKTR) was quite the outperformer on the stock exchange for the second day in a row. On Wednesday, one day after ...

The latest biotech stock to explode in price, Nektar Therapeutics (NKTR 1.20%) was quite the outperformer on the stock exchange for the second day in a row. On Wednesday, one day after delivering ...

SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotech with a market capitalization of $119 million, will host an investor call tomorrow to present top-line data from the 16-week ...

Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025 ...

Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic ...

Nektar is on track to announce topline results from its Phase 2b trials for REZPEG in atopic dermatitis and alopecia areata in June and December 2025, respectively.

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to ...

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to ...

Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025 ...